This bill amends Minnesota Statutes 2024, section 256B.0625, subdivision 13g, to require that nonopioid drugs approved by the United States Food and Drug Administration (FDA) for the treatment or management of pain are not disadvantaged in coverage compared to opioid or narcotic drugs on the preferred drug list. Specifically, the commissioner must ensure that nonopioid drugs are not designated as nonpreferred if any opioid or narcotic drug is preferred, and that the utilization management protocols for nonopioid drugs are not more restrictive than those for opioids. The bill also clarifies that this requirement applies immediately upon FDA approval of a nonopioid drug, regardless of its review status by the commissioner or the Formulary Committee.

Additionally, the bill includes several insertions that enhance the process for managing the preferred drug list. It mandates that the commissioner consider the implications of any changes to the drug list on public health policies and health disparities, and requires public hearings before any deletions or modifications are made. The bill also stipulates that adequate public notice must be provided prior to these hearings, ensuring transparency in the decision-making process regarding the preferred drug list.

Statutes affected:
Introduction: 256B.0625